Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Haven House (T’àa Shuyee Hit), Allen Court (Shaanáx̱ Tlein), and Alaway Avenue (Eix’gul’héen Hit). Allen Court and Alaway Avenue are shelters for men reentering society. Each of the ...

InflammX Therapeutics, Inc. has entered into an option agreement granting Bausch + Lomb the right to acquire the company. InflammX’s pipeline includes an orally dosed therapeutic candidate targeting ...

After hours: January 17 at 6:47:44 PM EST Loading Chart for BLCO ...